Influence of cardiac function, inflammatory factor and matrix metalloproteinases in chronic heart failure patients with the treatment of rosuvastatin
Objective: To explore the influence of cardiac function,inflammatory factor and matrix metalloproteinases (MMP) in chronic heart failure (CHD) patients with the treatment of rosuvastatin. Methods: Chose 100 cases of CHF as the research object, they were divided into observation group and control gro...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Editorial Board of Journal of Hainan Medical University
2016-05-01
|
Series: | Journal of Hainan Medical University |
Subjects: | |
Online Access: | http://www.hnykdxxb.com/PDF/201610/8.pdf |
id |
doaj-4623bc9ff0d54697827ec0897d6aa0dc |
---|---|
record_format |
Article |
spelling |
doaj-4623bc9ff0d54697827ec0897d6aa0dc2020-11-24T21:38:52ZengEditorial Board of Journal of Hainan Medical UniversityJournal of Hainan Medical University1007-12371007-12372016-05-0122102730Influence of cardiac function, inflammatory factor and matrix metalloproteinases in chronic heart failure patients with the treatment of rosuvastatinJie Xu0Xiao-Mei Luo1Qiang Hu2Department of Cardiology, Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, ChinaDepartment of Cardiology, Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, ChinaDepartment of Cardiology, Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, ChinaObjective: To explore the influence of cardiac function,inflammatory factor and matrix metalloproteinases (MMP) in chronic heart failure (CHD) patients with the treatment of rosuvastatin. Methods: Chose 100 cases of CHF as the research object, they were divided into observation group and control group according to random number table method , 50 cases in each group, patients in two groups were given routine CHF treatment, on this basis, patients in the observation group were given rosuvastatin, they were treated for 6 months, compared the cardiac function indexes: left ventricular ejection fraction (LVEF), left ventricular enddiastolic diameter (LVEDD) and left ventricular end systolic diameter (LVESD), inflammatory factor: high sensitivity C-reactive protein (hs-CRP) and interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) and MMPS: MMP-2 and MMP-9 in two groups before and after treatment. Results: The levels of LVEF in observation group after treatment was significantly higher than before and the control group after treatment,the levesls of LVEDD, LVESD, hs-CRP, IL-6, TNF-α, MMP-2 and MMP-9 were significantly lower than before and the control group after treatment, the differences were statistically significant; The levels of LVEF in control group after treatment were significantly higher while the levels of LVEDD, LVESD, MMP-2 and MMP-9 were significantly lower than before the treatment, the differences were statistically significant. Conclusion: Rosuvastatin can significantly improve cardiac function in patients with CHF, it may related to its inhibitory effect of inflammation and ventricular remodeling. http://www.hnykdxxb.com/PDF/201610/8.pdfRosuvastatinChronic heart failureCardiac functionInflammatory factorMatrix metalloproteinases |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jie Xu Xiao-Mei Luo Qiang Hu |
spellingShingle |
Jie Xu Xiao-Mei Luo Qiang Hu Influence of cardiac function, inflammatory factor and matrix metalloproteinases in chronic heart failure patients with the treatment of rosuvastatin Journal of Hainan Medical University Rosuvastatin Chronic heart failure Cardiac function Inflammatory factor Matrix metalloproteinases |
author_facet |
Jie Xu Xiao-Mei Luo Qiang Hu |
author_sort |
Jie Xu |
title |
Influence of cardiac function, inflammatory factor and matrix metalloproteinases in chronic heart failure patients with the treatment of rosuvastatin |
title_short |
Influence of cardiac function, inflammatory factor and matrix metalloproteinases in chronic heart failure patients with the treatment of rosuvastatin |
title_full |
Influence of cardiac function, inflammatory factor and matrix metalloproteinases in chronic heart failure patients with the treatment of rosuvastatin |
title_fullStr |
Influence of cardiac function, inflammatory factor and matrix metalloproteinases in chronic heart failure patients with the treatment of rosuvastatin |
title_full_unstemmed |
Influence of cardiac function, inflammatory factor and matrix metalloproteinases in chronic heart failure patients with the treatment of rosuvastatin |
title_sort |
influence of cardiac function, inflammatory factor and matrix metalloproteinases in chronic heart failure patients with the treatment of rosuvastatin |
publisher |
Editorial Board of Journal of Hainan Medical University |
series |
Journal of Hainan Medical University |
issn |
1007-1237 1007-1237 |
publishDate |
2016-05-01 |
description |
Objective: To explore the influence of cardiac function,inflammatory factor and matrix metalloproteinases (MMP) in chronic heart failure (CHD) patients with the treatment of rosuvastatin. Methods: Chose 100 cases of CHF as the research object, they were divided into observation group and control group according to random number table method , 50 cases in each group, patients in two groups were given routine CHF treatment, on this basis, patients in the observation group were given rosuvastatin, they were treated for 6 months, compared the cardiac function indexes: left ventricular ejection fraction (LVEF), left ventricular enddiastolic diameter (LVEDD) and left ventricular end systolic diameter (LVESD), inflammatory factor: high sensitivity C-reactive protein (hs-CRP) and interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) and MMPS: MMP-2 and MMP-9 in two groups before and after treatment. Results: The levels of LVEF in observation group after treatment was significantly higher than before and the control group after treatment,the levesls of LVEDD, LVESD, hs-CRP, IL-6, TNF-α, MMP-2 and MMP-9 were significantly lower than before and the control group after
treatment, the differences were statistically significant; The levels of LVEF in control group after treatment were significantly higher while the levels of LVEDD, LVESD, MMP-2 and MMP-9 were significantly lower than before the treatment, the differences were statistically significant. Conclusion: Rosuvastatin can significantly improve cardiac function in patients with CHF, it may related to its inhibitory effect of inflammation and ventricular remodeling.
|
topic |
Rosuvastatin Chronic heart failure Cardiac function Inflammatory factor Matrix metalloproteinases |
url |
http://www.hnykdxxb.com/PDF/201610/8.pdf |
work_keys_str_mv |
AT jiexu influenceofcardiacfunctioninflammatoryfactorandmatrixmetalloproteinasesinchronicheartfailurepatientswiththetreatmentofrosuvastatin AT xiaomeiluo influenceofcardiacfunctioninflammatoryfactorandmatrixmetalloproteinasesinchronicheartfailurepatientswiththetreatmentofrosuvastatin AT qianghu influenceofcardiacfunctioninflammatoryfactorandmatrixmetalloproteinasesinchronicheartfailurepatientswiththetreatmentofrosuvastatin |
_version_ |
1725934051182772224 |